The claims in the patent cover, among other inventions, Acura’s IMPEDE Technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine. This
XGEVA was approved and granted Orphan Drug Designation by the FDA, which is reserved for drugs that are intended for the treatment of rare diseases affecting fewer than
Under the terms of the agreement, Biopharm will market NeutroPhase in Egypt, Saudi Arabia, Algeria, Sudan and Libya. Saudi Arabia, in particular, is a large potential market for
Data for the recombinant factor VIII (rFVIII) product NovoEight® were presented at the 56th Annual Meeting of the American Society of Hematology (ASH). The post hoc analysis from
In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete
Results showed high levels of response in patients with relapsed or refractory classical Hodgkin Lymphoma (HL), with an overall response rate of 87% (n=20) and stable disease in
AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can
The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral
MRIGlobal will lead a team that will produce the vaccine to be used in a Phase I clinical trial. HPV can cause genital warts and cancer; it is
BAY 81-8973 is a full-length recombinant factor VIII which has demonstrated clinical evidence of efficacy when used for prophylaxis twice or three times per week, with standard dosages.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.